Breaking Hedge Fund News






Each business day HedgeCo.Net keeps you informed with the top hedge fund industry news, opinion and insight from around the globe. From the latest hedge fund launches, to the impact of regulation, competition, and investor activism - we track the topics and people that make a difference to you.

Explore the most informative hedge fund articles and take the news with you, using HedgeCo's Hedge Fund News RSS

Still want more? Browse the hedge fund blogs, authored by hedge fund industry experts.


News Categories
Today is Monday, February 13, 2012 at 
- Countdown to Market Close:
Posts Tagged ‘natural-gas-prices’

Hedge Fund Bets Millions Natural Gas Price Will Rise

Thursday, August 20, 2009 : Permalink

Bloomberg – A hedge fund, whose name isn’t disclosed, has placed a large bet that natural gas prices will triple by the Northern Hemisphere winter just as the price of the commodity slides to a seven-year low, the Financial Times reported, which cited New York Mercantile Exchange traders.

Last week, the fund spent millions for the right to buy U.S. natural gas at $10 per million British thermal units in January and February, up from yesterday’s spot level of just above $3 per mBtu, according to the report.

Read Complete Article

Tags: , , , , , , , , , , ,

trackback from your site.

Icahn Biotech Stakes Rise on Drugmaker Demand as Markets Gyrate

Friday, September 26, 2008 : Permalink

Bloomberg – Carl Icahn, the investor angling to sell a 13 percent stake in Imclone Systems Inc. for more than $800 million, is piling up bets in the biotechnology industry.

Icahn and hedge funds he manages have accumulated stakes in at least 10 biotechnology companies that make up a fifth of the investors’ total publicly reported holdings, excluding shares of Icahn Enterprises LP. He and the funds have about $1.3 billion invested in biotech, four times as much as two years ago, and increased those bets by $320 million in the last two months alone, according to data compiled by Bloomberg.

The 72-year-old has made his personal fortune, estimated at $14.5 billion by Forbes magazine, by investing in companies and then pressuring management into selling their companies at higher share prices. The strategy worked for airlines, refiners and casinos. Icahn is now targeting biotech companies, whose products make them appealing to pharmaceutical giants, such as Bristol-Myers Squibb Co. and AstraZeneca Plc, that will be losing patent protection over the next four years on medicines with $84 billion in annual sales.

Read Complete Article

Related Posts Plugin for WordPress, Blogger...

Tags: , , , , , ,

trackback from your site.